{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:54:10Z","timestamp":1740174850630,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["surg case rep"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Few reports exist of the long-term management of recurrent and progressive papillary thyroid carcinoma (PTC) with a tyrosine kinase inhibitor for over 5\u00a0years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 57-year-old woman was referred to a psychiatric hospital for the treatment of schizophrenia. The patient had been diagnosed with a PTC at the age of 40 and subsequently underwent a left thyroid lobectomy. At 47, completion total thyroidectomy and lymph node dissection were performed and the patient assessed as radioactive iodine refractory postoperatively. External radiation therapy was performed for Rouviere lymph nodes. At 57, neck and mediastinal lymph nodes, and lung metastases had progressed, and the trachea became narrowed by para-tracheal lymph node compression. After 2\u00a0weeks of sorafenib therapy on an outpatient basis, the patient was discovered unconsciousness at home and transferred to hospital by ambulance; sorafenib therapy was stopped. The patient was diagnosed with reversible posterior leukoencephalopathy syndrome by brain magnetic resonance imaging. External radiation therapy to the site of the tracheal stenosis in the neck and mediastinum was performed. The patient\u2019s mental symptoms worsened, and she was referred to a psychiatric hospital, Kachi Memorial Hospital, in July 2015. In September, the patient\u2019s mental state stabilized and in November, after computed tomography revealed rapid disease progression, lenvatinib was commenced at a daily dose of 24\u00a0mg. Measurable solid recurrence sites were neck lymph nodes in the pre-laryngeal subcutaneous space, right lobe of the lung, and left adrenal. After 3\u00a0months, the tumors shrank in a partial response (PR). Because of several adverse events, occasional dose reductions or discontinuations of lenvatinib were sometimes necessary. Since re-starting lenvatinib, treatment with this for 51 consecutive months was achieved while maintaining a PR. Although a new bone metastasis was noted after 57\u00a0months of lenvatinib, treatment was continued for another 9\u00a0months. The patient subsequently passed away in June 2021.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The long-term treatment of recurrent PTC with lenvatinib was feasible, with manageable adverse events, for more than 5\u00a0years.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40792-022-01374-0","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T10:02:55Z","timestamp":1643277775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term management of recurrent papillary thyroid carcinoma treated with lenvatinib for over 5\u00a0years: a case report"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5988-147X","authenticated-orcid":false,"given":"Tsuneo","family":"Imai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsu","family":"Senaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiharu","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"issue":"9940","key":"1374_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319\u201328.","journal-title":"Lancet"},{"issue":"7","key":"1374_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621\u201330.","journal-title":"N Engl J Med"},{"issue":"3","key":"1374_CR3","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.21873\/anticanres.14932","volume":"41","author":"N Fukuda","year":"2021","unstructured":"Fukuda N, Toda K, Ohmoto A, Wang X, Hayashi N, Urasaki T, et al. Baseline tumour size as a prognostic factor for radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Anticancer Res. 2021;41(3):1683\u201391.","journal-title":"Anticancer Res"},{"issue":"2","key":"1374_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s12020-021-02634-z","volume":"73","author":"T Porcelli","year":"2021","unstructured":"Porcelli T, Luongo C, Sessa F, Klain M, Masone S, Troncone G, et al. Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution. Endocrine. 2021;73(2):358\u201366.","journal-title":"Endocrine"},{"issue":"1","key":"1374_CR5","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1186\/s12885-018-4612-2","volume":"18","author":"M Tori","year":"2018","unstructured":"Tori M, Shimo T. Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report. BMC Cancer. 2018;18(1):698.","journal-title":"BMC Cancer"},{"issue":"1","key":"1374_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12957-019-1626-4","volume":"17","author":"NW Sheu","year":"2019","unstructured":"Sheu NW, Jiang HJ, Wu CW, Chiang FY, Chiou HC, Hsiao PJ. Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review. World J Surg Oncol. 2019;17(1):84.","journal-title":"World J Surg Oncol"},{"key":"1374_CR7","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 11). Eur J Cancer. 2009;45(2):228\u201347.","DOI":"10.1016\/j.ejca.2008.10.026"},{"issue":"23","key":"1374_CR8","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1200\/JCO.2016.71.6472","volume":"35","author":"MS Brose","year":"2017","unstructured":"Brose MS, Worden FP, Newbold KL, Guo M, Hurria A. Effect of Age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial. J Clin Oncol. 2017;35(23):2692\u20139.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1374_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1530\/ERC-18-0049","volume":"25","author":"AG Gianoukakis","year":"2018","unstructured":"Gianoukakis AG, Dutcus CE, Batty N, Guo M, Baig M. Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr Relat Cancer. 2018;25(6):699\u2013704.","journal-title":"Endocr Relat Cancer"},{"key":"1374_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2019.05.031","volume":"118","author":"LD Locati","year":"2019","unstructured":"Locati LD, Piovesan A, Durante C, Bregni M, Castagna MG, Zovato S, et al. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur J Cancer. 2019;118:35\u201340.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1374_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/EJE-19-0763","volume":"182","author":"MD Aydemirli","year":"2020","unstructured":"Aydemirli MD, Kapiteijn E, Ferrier KRM, Ottevanger PB, Links TP, van der Horst-Schrivers ANA, et al. Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data. Eur J Endocrinol. 2020;182(2):131\u20138.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1374_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s12020-020-02290-9","volume":"69","author":"F Jerkovich","year":"2020","unstructured":"Jerkovich F, Califano I, Bueno F, Carrera JM, Giglio R, Abelleira E, et al. Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina. Endocrine. 2020;69(1):142\u20138.","journal-title":"Endocrine"},{"issue":"2","key":"1374_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1089\/thy.2019.0221","volume":"30","author":"C Masaki","year":"2020","unstructured":"Masaki C, Sugino K, Saito N, Akaishi J, Hames KY, Tomoda C, et al. Efficacy and limitations of lenvatinib therapy for radioiodine-refractory differentiated thyroid cancer: real-world experiences. Thyroid. 2020;30(2):214\u201321.","journal-title":"Thyroid"},{"key":"1374_CR14","doi-asserted-by":"publisher","first-page":"8834148","DOI":"10.1155\/2020\/8834148","volume":"2020","author":"G Rendl","year":"2020","unstructured":"Rendl G, Sipos B, Becherer A, Sorko S, Trummer C, Raderer M, et al. Real-world data for lenvatinib in radioiodine-refractory differentiated thyroid cancer (RELEVANT): a retrospective multicentric analysis of clinical practice in Austria. Int J Endocrinol. 2020;2020:8834148.","journal-title":"Int J Endocrinol"},{"issue":"5","key":"1374_CR15","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1089\/thy.2019.0476","volume":"30","author":"E Song","year":"2020","unstructured":"Song E, Kim M, Kim EY, Kim BH, Shin DY, Kang HC, et al. Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: a multicenter study in Korea. Thyroid. 2020;30(5):732\u20138.","journal-title":"Thyroid"},{"issue":"2","key":"1374_CR16","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s12020-020-02477-0","volume":"72","author":"S De Leo","year":"2021","unstructured":"De Leo S, Di Stefano M, Persani L, Fugazzola L, Colombo C. Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival. Endocrine. 2021;72(2):462\u20139.","journal-title":"Endocrine"},{"issue":"2","key":"1374_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12149-011-0553-4","volume":"26","author":"T Higashi","year":"2012","unstructured":"Higashi T, Kudo T, Kinuya S. Radioactive iodine (131I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective. Ann Nucl Med. 2012;26(2):99\u2013112.","journal-title":"Ann Nucl Med"},{"issue":"5","key":"1374_CR18","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.21037\/gs-20-378","volume":"9","author":"T Okamoto","year":"2020","unstructured":"Okamoto T, Omi Y, Yoshida Y, Horiuchi K, Abe K. Radioactive iodine treatment of papillary thyroid carcinoma in Japan. Gland Surg. 2020;9(5):1698\u2013707.","journal-title":"Gland Surg"},{"issue":"12","key":"1374_CR19","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/RLU.0b013e31818bf146","volume":"33","author":"Y Tachi","year":"2008","unstructured":"Tachi Y, Iwano S, Kato K, Tadokoro M, Naganawa S. Diagnostic whole-body scanning before radioiodine therapy for pulmonary metastases of differentiated thyroid cancer: predictive value and recommendations. Clin Nucl Med. 2008;33(12):845\u201351.","journal-title":"Clin Nucl Med"},{"issue":"7","key":"1374_CR20","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/RLU.0000000000002078","volume":"43","author":"K Nakanishi","year":"2018","unstructured":"Nakanishi K, Kikumori T, Miyajima N, Takano Y, Noda S, Takeuchi D, et al. Impact of patient age and histological type on radioactive iodine avidity of recurrent lesions of differentiated thyroid carcinoma. Clin Nucl Med. 2018;43(7):482\u20135.","journal-title":"Clin Nucl Med"},{"key":"1374_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejca.2020.12.032","volume":"147","author":"M Tahara","year":"2021","unstructured":"Tahara M, Kiyota N, Hoff AO, Badiu C, Owonikoko TK, Dutcus CE, et al. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer. 2021;147:51\u20137.","journal-title":"Eur J Cancer"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-022-01374-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40792-022-01374-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-022-01374-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T10:08:10Z","timestamp":1643278090000},"score":1,"resource":{"primary":{"URL":"https:\/\/surgicalcasereports.springeropen.com\/articles\/10.1186\/s40792-022-01374-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1374"],"URL":"https:\/\/doi.org\/10.1186\/s40792-022-01374-0","relation":{},"ISSN":["2198-7793"],"issn-type":[{"type":"electronic","value":"2198-7793"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"1 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report was conducted in accordance with the Declaration of Helsinki and procedures were performed in accordance with the ethical standards of our institution and our national standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from the patient for the publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}